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Susceptibility to common human diseases is influenced by both genetic and
environmental factors. The explosive growth of genetic data, and the knowl-
edge that it is generating, are transforming our biological understanding of
these diseases. In this review, we describe the technological and analytical
advances that have enabled genome-wide association studies to be successful
in identifying a large number of genetic variants robustly associated with
common disease. We examine the biological insights that these genetic associ-
ations are beginning to produce, from functional mechanisms involving
individual genes to biological pathways linking associated genes, and the
identification of functional annotations, some of which are cell-type-specific,
enriched in disease associations. Although most efforts have focused on iden-
tifying and interpreting genetic variants that are irrefutably associated with
disease, it is increasingly clear that—even at large sample sizes—these rep-
resent only the tip of the iceberg of genetic signal, motivating polygenic
analyses that consider the effects of genetic variants throughout the genome,
including modest effects that are not individually statistically significant. As
data from an increasingly large number of diseases and traits are analysed,
pleiotropic effects (defined as genetic loci affecting multiple phenotypes) can
help integrate our biological understanding. Looking forward, the next gener-
ation of population-scale data resources, linking genomic information with
health outcomes, will lead to another step-change in our ability to understand,
and treat, common diseases.
1. Introduction
Genetics plays a role in susceptibility to all common human diseases and tomany
other complex human traits. The genetic variants an individual inherits are only
part of the story of disease susceptibility—most common diseases are 30–60%
heritable—with lifestyle and dietary factors, and other environmental exposures,
also playing an important role.
The last decade has seen an explosion in our knowledge of genetic variants
associated with common diseases. Critical to this has been the ability to measure
genetic variation at hundreds of thousands of markers across the human genome,
in large numbers of individuals. Genome-wide association studies (GWAS)
exploited these technological developments in large case-control studies, with
unprecedented success.
In this review,we provide the background toGWAS and describe their success
in identifying specific variants associated with disease, in assessing the total con-
tribution of common variants to disease susceptibility, and in revealing often
surprising genetic links between diseases. EachGWAS association potentially pro-
vides novel biological insights into disease pathophysiology, and potentially into
novel therapeutic targets. Understanding of the biology underpinning GWAS
associations has lagged behind their discovery, but even the limited number of
new and in many cases unexpected biological findings that have followed from
GWAS make it clear that the potential benefits are huge.
& 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
Prior to the GWAS era, there were two main approaches to
understanding the genetic basis of common diseases. In spite
of extensive research efforts, neither proved particularly fruitful.
First, linkage studies searched for large disease-predisposing
haplotypes shared among related affected individuals, with lim-
ited success. Linkage analysis is not well powered to identify
common variants of modest effect, thus it did not detect the
findings of subsequent GWAS [1]. Second, candidate-gene
association studies focused on a specific gene or region of the
genome and assessed variation in that gene/region for associ-
ation with disease. While there were some successes, notably in
breast cancer, most studies were based on what we now know
to be poor choices of candidate loci, were underpowered, and/
orwere susceptible to confounding, leading to false-positive find-
ings that failed to replicate [2]. Thus, prior to 2005, common
variants reliably associated with susceptibility to common dis-
ease were largely limited to large-effect loci, such as the MHC
in autoimmune disease, APOE in Alzheimer’s and other
diseases, and the sickle mutation for malaria susceptibility.
2. Genome-wide association studies
The ability to assay genome-wide genetic variation in large
numbers of individuals has transformed our knowledge
of the genetic architecture of common human diseases [1].
Several developments over the last decade have led to a
dramatic increase in our knowledge.
The realization that there are extensive local correlations
(called ‘linkage disequilibrium’) between nearby variants
in the human genome led to the International HapMap
Project [3], a major collaborative effort to map patterns
of genetic variation in several global population groups.
Critically, the extent of linkage disequilibrium in human
populations means that much of the common variation in
the genome (by convention, ‘common’ refers to variants
with minor allele frequency (MAF) . 5%) can be assessed
by directly typing only a subset of variation. For example, a
carefully chosen set of approximately 500 000 SNPs covers
over 80% of common variation in populations of European
ancestry [4].
Parallel technological developments in array technologies,
in part prompted by the HapMap project, allowed assays
for hundreds of thousands of single-nucleotide polymorph-
isms (SNPs) in a single experiment. These SNP arrays were
game-changing. They allowed, for the first time, a systematic,
genome-wide assessment of the role of common genetic
variation in human disease.
GWAS used SNP arrays to type hundreds of thousands
of SNPs in large numbers of cases and controls for common
diseases of interest. GWAS look for SNPs with statistically
significant allele frequency differences between cases and
controls. (The intuition is simple: if an allele increases suscep-
tibility to a particular disease, that allele should be more
common in cases than controls.) For quantitative traits,
GWAS assess the correlation between SNP genotypes and
trait values. The first GWAS were published in 2005, and
within a few years there were over 100 DNA variants associ-
ated with disease susceptibility. There are now over 10 000
published genome-wide associations through December 2013 
published GWA at p < 5 × 10–8 for 17 trait categories
digestive system disease
cardiovascular disease
metabolic disease
immune system disease
nervous system disease
liver enzyme measurement
lipid or lipoprotein measurement
inflammatory marker measurement
haematological measurement
body measurement
cardiovascular measurement
other measurement
response to drug 
biological process
cancer
other disease
other trait
Figure 1. The NHGRI GWA catalogue. Published associations are displayed by chromosome and colour-coded by class of phenotype. As of December 2013, the
catalogue included 11 912 SNPs that were significant at p, 1025 and 6400 SNPs that were genome-wide significant ( p, 5  1028) [5]. Currently, the
catalogue includes approximately 9400 genome-wide significant SNPs.
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published associations, across hundreds of diseases and
quantitative traits (figure 1; see also Web resources) [5].
To minimize false-positive findings, the field (or in practice
its journal editors) have insisted on two criteria for declaring
an association to be genuine. First, the association must meet
stringent levels of statistical significance (e.g. p, 5  1028).
This has often been justified on the basis ofmultiple hypothesis
testing [6], although others (including some of the current
authors) have argued the multiple testing paradigm is not
appropriate in the GWAS context (in brief, in assessing evi-
dence for association with a particular SNP on chromosome
1, say, why should it matter whether one also looks at evidence
for a completely different SNP on, say, chromosome 16?), but
that stringent thresholds are nonetheless warranted due to the
low prior probability of association (see box 1 in [7]). Second,
the association must be replicated in a separate sample of cases
and controls, ideally using a different genotyping technology
to minimize the possibility of assay artefacts [8]. As a conse-
quence of these criteria, along with extensive efforts to perform
careful quality control and correct for confounding factors
such as population stratification, the vast majority of published
GWAS associations have proved to be real.
Most variants discovered by GWAS have relatively small
effects on disease susceptibility, with typical odds ratios of
1.1 or lower, and rarely above 1.3. It has become clear (see
below) that for a typical common human disease there will
be a large number of SNPs that each have a small (but non-
zero) effect on disease risk. Since power to detect an association
depends on sample size and allele frequency, increasing the
size of GWAS studies for a particular disease will lead to
further discovery of associated variants. For relatively small
GWAS size, one of the key factors driving success is the
number of SNPs with common risk alleles at the top end of
theGWAS range of effect size, whichwill differ across diseases.
For example, early studies of age-relatedmacular degeneration
were successful with quite small sample sizes [9]. GWAS
studies of a few thousand individuals have tended to yield
reasonable numbers of associations for some autoimmune
diseases, intermediate numbers of associations for diseases
such as type 2 diabetes and heart disease, and small numbers
(often none) for neuro-psychiatric disorders. At larger sample
sizes, GWAS studies have been very successful, even
in neuro-psychiatric diseases (e.g. a recent primary GWAS
of 34 241 individuals with schizophrenia and 45 604 controls
yielded 108 associations [10]).
The realization that sample size is a critical factor in
GWAS success created strong incentives for groups studying
a particular disease to collaborate by pooling their samples
(e.g. by meta-analysing their association results). One positive
side effect of the GWAS era is that there are now major global
consortia in place to tackle the genetic basis of particular dis-
eases, often involving tens of thousands of disease cases
(or hundreds of thousands of individuals for quantitative
traits); in some instances, the genotyping of large samples
has been facilitated by cost-effective specialty chips targeting
variants that were highly ranked in previous studies of rela-
ted traits. Early in the GWAS era, there was debate about the
relative merits of small, exquisitely phenotyped disease collec-
tions when compared with larger samples with limited or less
precise phenotype information available. From a statistical
perspective, this reduces to a question about noise and study
power, and it has become clear that noise in the phenotype
measurement can often be more than offset by large sample
sizes. Even studies with self-reported phenotypes can be
successful for at least some diseases [11].
One important methodological development for GWAS
studies has been genotype imputation, introduced in 2007
[12]. Imputation further leverages the correlations between
nearby alleles due to linkage disequilibrium. First, a relatively
small sample of individuals (called a reference panel) is typed
at a dense set of SNPs or directly sequenced. Then, given a
much larger target sample of individuals typed at only a
subset of the SNPs, knowledge of the correlation structure
in the reference panel can be combined with the data from
the target sample to predict, or impute, genotypes at untyped
SNPs in the target sample. The accuracy of the imputed gen-
otypes at untyped common variants is typically very high
(e.g. r2 ¼ 0.96 between imputed and true genotypes for
common SNPs imputed using European reference samples
from HapMap 3) [13]. Imputation accuracy decreases for
low-frequency (0.5%,MAF, 5%) and rare (MAF, 0.5%)
variants, but the latest imputation methods still perform
well for many of these variants, and accuracy will increase
as reference panels grow larger. The 1000 Genomes reference
panel [14] is currently widely used, but larger reference
panels such as the Haplotype Reference Consortium (see
Web resources) are now available. In the context of GWAS,
there have been two main uses of imputation. The first is to
combine studies that use different genotyping arrays—SNPs
typed in one study but not the other can be imputed in the
other study to facilitate meta-analyses. The second is to use
imputation from available reference panels to dramatically
increase the number of variants for which genotype data
are available for association testing (and fine-mapping; see
below). Figure 2 illustrates part of the output from a GWAS
study, called a Manhattan plot, in this case giving the
strength of evidence of association of a phenotype with a
dense set of imputed and directly genotyped SNPs.
Despite extensive study, relatively little is currently
known about the underlying biological triggers and pro-
cesses that lead to most diseases. Each GWAS association
provides a potential clue about these mechanisms. If carrying
one or two copies of a particular allele increases risk of a dis-
ease (relative to individuals not carrying that allele), then it
should be possible to understand the different functional
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Figure 2. Manhattan plots from dense imputed data. A Manhattan plot for
chromosome 4 for a GWAS of height in the UK Biobank imputed dataset of
approximately 73 000 000 genetic variants (genome-wide) in approximately
150 000 individuals. The plot is adapted from fig. 3 in the document ‘UK
Biobank phasing and imputation documentation’, written by J. Marchini
(see Web resources).
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consequences, at a molecular and physiological level, of car-
rying that allele. In turn, this understanding can shed light on
disease processes, and potentially point to novel targets for
drug therapies. Progress in this harvesting of GWAS associ-
ations for novel biological insights has lagged considerably
behind the rate of novel GWAS discovery. We discuss the
reasons for this in the next section—it is a hard problem—
and provide examples of some of the biological insights
that have already arisen from GWAS findings. Assessment
of the ultimate impact of GWAS discovery will be clearer
when we have travelled further down the road of uncovering
the underlying biology.
3. Biological insights from genome-wide
association studies
It has become clear that changes in gene regulation, rather
than changes to the proteins produced by genes, are at the
heart of the biology underlying most GWAS associations
(for example, top GWAS signals predominantly lie in inter-
genic and intronic regions). Owing to our lack of detailed
knowledge of (and tools for studying) the biology of gene
regulation, it has not been straightforward to move from
GWAS findings to the underlying biological mechanisms,
or even to definitive identification of the gene involved and
direction of gene regulation effect. An added complication
is that gene regulation effects are often tissue-specific, and
for many diseases the appropriate tissue(s) or cell type(s)
are not known precisely and/or are inaccessible and difficult
to study. For example, for coronary artery disease, relevant
tissue/cell types that could mediate genetic susceptibility
include liver/hepatocytes (e.g. through involvement in lipo-
protein metabolism, source of inflammatory cytokines), cells
of the immune system (lymphocytes, macrophages), platelets
and cells of the vessel wall, including smooth muscle cells
and endothelial cells. Moreover, the biological mechanisms
could operate at any stage of the individual’s development
and adult life (e.g. for neuro-psychiatric conditions, either
brain development and/or adult brain could be important).
For diseases involving the immune system (including but
not exclusively autoimmune diseases) what is most relevant
may be the way in which a specific immune cell type reacts
to a particular external stimulus.
Although linkage disequilibrium is helpful at the stage of
GWAS discovery (see above), it complicates GWAS follow-
up: a GWAS discovery typically points to a region of linkage
disequilibrium spanning tens of thousands of base pairs and
tens of correlated SNPs, any of which could be driving the
underlying molecular mechanism. GWAS results generally
do not distinguish between the set of highly correlated
SNPs. Further genetic study can be helpful, via fine-mapping,
in which additional samples are typed at a denser set of SNPs
in an effort to pinpoint causal variants. Fine-mapping is par-
ticularly effective when carried out in multiple ethnicities,
because patterns of linkage disequilibrium (arising from
shared ancestry) differ between populations. In a population
different from the discovery sample, the biologically causal
SNP may be in linkage disequilibrium with a different set
of SNPs, thus reducing the overall set of potential proxy
SNPs [15].
Despite these challenges, GWAS have produced valuable
biological insights about the pathways involved in a
particular disease, the functional mechanisms of (regulation
of) a particular gene affecting the disease, and the functional
and cell-type-specific enrichments for variants associated
with the disease. Below, we discuss each of these in turn.
(a) Biological pathways
Because much gene regulation acts in cis, biologically causal
genes will often be physically close to the most associated
GWAS SNP. GWAS associations are sometimes labelled by
the closest gene, or by a nearby gene thought to be a good
candidate for the disease or trait in question. This is often
used in the field as a convenient shorthand in describing
the association—it is not typically intended as a statement
about the underlying biological basis for the association,
nor should it be interpreted in this way. Nonetheless, the
set of genes near a GWAS association is likely to be highly
enriched for causal genes. One feature that became clear
early in the GWAS era is that many of these potentially
causal genes had not figured on the lists compiled by experts
of likely candidate genes for the diseases in question, and
hence that GWAS findings were pointing to genuinely
novel biological insights for human disease.
Through a range of formal and informal analyses, exam-
ination of gene sets arising from GWAS findings have
implicated specific and often novel pathways as being
important for diseases studied. We illustrate just a few of
many such examples. GWAS pointed to the previously unrea-
lized importance of autophagy in Crohn’s disease, and
more generally has highlighted the importance of innate
immune pathways in this condition [16]. In multiple sclerosis,
GWAS confirmed a primary role for adaptive immunity, with
surprisingly few neuronal hits [17], a finding reinforced by
the overlap between GWAS variants for multiple sclerosis
and those for other autoimmune diseases (see Pleiotropy sec-
tion below for other instances of insights from comparisons
of GWAS findings across diseases). In type 2 diabetes, the
majority of GWAS loci appear to act primarily through
defects in insulin secretion (implicating the pancreatic beta-
cells) with unexpected pathways appearing to play key
roles in disease pathogenesis, including cell cycle regulation
and CREBBP-related transcription factor activity [18]. Parallel
analyses of GWAS loci for glycaemic traits revealed the sur-
prising finding that while many loci that affect levels of
fasting glucose in non-diabetic individuals also affect risk of
type 2 diabetes, some do not [19], indicating that the mechan-
ism by which glucose homeostasis is disturbed, rather than
simply the change in glucose levels, may be relevant to the
pathophysiology of type 2 diabetes. Going forward, pathway
analyses will continue to play a key role in interpretation of
GWAS findings [20].
(b) Functional mechanisms
Most GWAS loci contain common non-coding variants of
modest effect whose signals span multiple genes. However,
there are some examples where the top GWAS hit at a locus,
or a SNP in strong linkage disequilibrium with it, is a protein-
altering coding variant (e.g. the association at IL23R for
Crohn’s disease), and others where there is a second signal of
association, independent of the main GWAS signal, caused by
a protein-altering variant in one of the genes in the GWAS
locus. These settings suggest both an obvious functional mech-
anism and gene of action. In other cases, loci may contain both
rspb.royalsocietypublishing.org
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regulatory variants for a particular gene and coding variants
within that gene. For example, several GWAS loci for type 2 dia-
betes contain genes known to harbour causal coding variants
for rare Mendelian syndromes related to type 2 diabetes
(e.g. HNF1A, HNF1B, WFS1, PPARG, KCNJ11, HNF4A, GCK).
In this case, a natural hypothesis is that the protein-coding
change in each gene that causes the rare syndrome has a large
effect on phenotype, whereas the (unknown) causal variant
underlying the GWAS association affects regulation of the
samegene andhas a smaller effect on the disease.More broadly,
conditional joint analyses of GWAS significant loci have often
identified multiple independent signals at the locus [21].
GWAS findings and biological follow-up have suggested
new treatment approaches for sickle cell disease (SCD), a sub-
stantial cause of mortality (176 000 deaths in 2013 [22]) and
morbidity globally. SCD was first described over 100 years
ago—and more than 60 years ago, it became arguably the
first example of a disease where the underlying molecular
basis was known—but in spite of intensive efforts, efficacious
treatments for the disease have remained elusive. Although
SCD is a Mendelian condition, novel biological insights
arising from GWAS of a related trait have radically trans-
formed the search for a treatment. Humans normally have
several different types of haemoglobin. One type, haemo-
globin F (HbF, fetal haemoglobin) predominates during
fetal development and early life. At about six weeks of age,
there is a switch (the ‘haemoglobin switch’) from HbF to hae-
moglobin A (HbA), which dominates throughout life. After
this switch, there remain low levels of circulating HbF, with
the exact amount differing between individuals. It had been
observed that individuals with SCD (and also individuals
with b-thalassemia) with higher levels of HbF suffer
less severe symptoms, leading to treatments that aim to
increase HbF levels. In parallel, there had been a long-
standing, but largely unsuccessful interest in understanding
the mechanism behind the haemoglobin switch, in the hope
of fully or partially reversing it. Two GWAS treating levels
of HbF as a quantitative trait identified the gene BCL11A
[23,24], a transcription factor that had not previously been
suggested as a player in the haemoglobin switch. A series
of elegant studies have subsequently shown that production
of HbF is controlled in a dosage-sensitive manner by
BCL11A, and that inactivation of BCL11A in a mouse
model for SCD corrects the defects associated with SCD by
inducing HbF production [25], suggesting a natural focus
for therapeutic intervention. It is worth noting that although
SCD (and b-thalassemia) primarily affect individuals of non-
European ancestry, the critical GWAS were undertaken in
European ancestry groups. GWAS link genetic variation to
phenotypes of interest, potentially leading to new biological
understanding that will often be relevant across human
populations, not just the population in which the GWAS
was undertaken.
The 8q24 locus implicated in several common cancers pro-
vides another example of valuable biological insights. The
locus was initially associated with prostate cancer, and later
shown to harbour multiple independent variants influencing
prostate cancer risk [26–28]. Subsequent studies showed that
the locus is also associated with colorectal, breast, ovarian
and bladder cancers [9,29,30]. Functional analyses have impli-
cated a transcriptional enhancer involved in long-range
interaction with theMYC oncogene and determined that mice
lacking this enhancer are resistant to intestinal tumours [12,31].
A partial list summarizing some of the early successful
approaches, and the resulting insights about functional mech-
anisms gained from GWAS, is provided in the electronic
supplementary material, table S1.
A commonly expressed misconception about GWAS
findings is that the small effect sizes at GWAS loci (which
typically explain less than 1% of trait variance) are too
small to be biologically interesting, or to be useful as drug
targets. However, effect size and biological relevance are
two distinct issues. Regardless of the effect size, each reliable
association of genetic variation with a particular phenotype is
the result of real biological mechanisms. Functional follow-up
of the association can be used to reveal the mechanism, typi-
cally leading to new insights into human biology and disease
pathophysiology, and potentially novel therapeutic targets
[32]. By contrast, observed effect sizes for common genetic
variants are a consequence of the interplay between the
mutational events that give rise to genetic variation, and
natural selection. If variants have large effects on disease
susceptibility and on other phenotypes affecting fitness,
then natural selection is likely to act to prevent those variants
from becoming common. A drug targeting that gene may per-
turb the gene more than the GWAS variant does, and hence
may have a larger effect on the downstream phenotype.
Indeed there are several existing examples of exactly this.
Statin drugs inhibit the enzyme HMGCo-A reductase. They
reduce levels of circulating LDL cholesterol, and have had a
substantial global impact on reducing cardiovascular disease.
GWAS of LDL cholesterol levels found an association near the
HMGCo-A reductase gene, but the GWAS variants had small
effects [33]. Other examples of successful drugs targeting
genes that arise (with small effect sizes) in GWAS include
PCSK9 for LDL cholesterol [33], and PPARG and KCNJ11 for
type 2 diabetes [18]. Each of these examples acts as a positive
control for the hypothesis that GWAS variants of small effect
can still point at effective drug targets.
(c) Functional enrichment and cell-type-specific effects
Analyses of all GWAS loci (instead of a single GWAS locus)
may also provide insights about functional mechanisms, by
determining which functional annotations are enriched for
association to disease. These analyses have largely focused
on regulatory annotations using data generated by the
ENCODE and Roadmap Epigenomics projects [34,35] to anno-
tate predicted regulatory elements (e.g. enhancers), which are
often cell-type-specific. One approach is to search for an enrich-
ment of GWAS hits in one type of functional element seen in
one cell type but not others. Several recent studies have
reported that GWAS loci (and loci that do not reach genome-
wide significance) exhibit cell-type-specific enrichments at
DNase I hypersensitivity sites (DHS), histone marks and
other regulatory elements. For example, variants associated
with rheumatoid arthritis are enriched for H3K4me3 marks
in CD4þ regulatory T cells [36], and variants associated with
schizophrenia, body mass index and smoking behaviour
are enriched for H3K27ac and other histone marks in brain
tissues [10,37]. This information can also be used to prioritize
causal variants, improving the efficacy of fine-mapping [38].
Most integrative analyses ultimately only provide suggestive
hypotheses of causal mechanisms, with detailed functional
follow-up being required to prove or support causality.
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4. The polygenic architecture of common disease
GWAS have consistently demonstrated that most common
diseases and traits are highly polygenic, with a large
number of underlying genetic variants that affect the disease
or trait [39]. As noted above, these common genetic variants
generally have very small effects that require large sample
sizes for detection [9] (with only a few exceptions). Further-
more, the set of associated variants often explain only a
small proportion of the genetic variation in the disease or
trait. For example, although the large schizophrenia study
described earlier identified 108 associated loci, these loci
collectively explain only 3% of the liability-scale variance of
schizophrenia, a highly heritable trait [10]. As we have
seen, the small effect sizes of associated variants do not
preclude important biological insights, but the incomplete
picture of the genetic architecture of diseases painted by the
known associated loci has motivated intense efforts to
explain the source of this ‘missing heritability’ [40].
An important step towards understanding the genetic
architecture of common diseases, starting in 2010, was
the use of statistical linear mixed models to estimate the herit-
ability explained by all common variants, not just those
associated at stringent statistical significance [41]. These
studies showed that common variants typically explain
roughly half of the narrow-sense heritability estimated from
twin studies, with the remainder likely to be due to rare var-
iants [42] (see below) and/or upward bias in twin-based
estimates [43]. In other words much, or potentially even
most, of the ‘missing heritability’ was not actually missing—
it was explained by the many common variants whose effect
sizes were small enough that they had not individually
reached statistical significance for association. Quantifying
the total number of common variants contributing non-zero
effects remains an ongoing challenge, with initial estimates
in the thousands for several traits [44]. Most studies of the
polygenic architecture of common disease have focused on
additive effects, as there is currently limited evidence of inter-
actions between alleles within a locus (dominance) or between
loci (epistasis).
5. Pleiotropy
The term pleiotropy is used to describe the phenomenon
whereby genetic variation at a single locus has an effect on
more than one phenotype. A related but different concept is
genetic correlation, defined as a correlation in direction and
magnitude of genetic effects. (Genetic correlation is a specific
measure of the extent to which genome-wide SNPs have the
same direction and magnitude of effect on two phenotypes.)
Some care is needed in differentiating different types of pleio-
tropy and genetic correlation in associations across traits [45],
particularly when the causal SNPs have yet to be identified.
When pleiotropy is observed, Mendelian randomization,
which employs significantly associated variants as instru-
mental variables, can be used to assess causal relationships
between risk factors and disease [46]. Some genes seem to
be particular foci for association with multiple phenotypes
(figure 3). These include genes whose function is at least
partially understood, such as the gene ABO (which deter-
mines the ABO blood group), where a complex pattern of
association is found with infectious diseases such as malaria,
red cell counts, inflammatory, lipid and liver biomarkers,
common cardiovascular disease and Grave’s disease [5].
Autoimmune disease encompasses a range of disorders
in which it is thought that immune and inflammatory mechan-
isms damage normal tissues in the body. GWAS have yielded
hundreds of loci across the genome that are robustly associated
with the risk of developing one or more of these disorders, and
it is therefore one of the areas where pleiotropy has been
studied most extensively. These analyses have shown that
many susceptibility alleles are shared across autoimmune dis-
orders [47,48]. Classifying shared associations according to
whether the direction of effect is the same or different between
phenotypes provides further evidence about the molecular
relationship between diseases [49]. One example is a putative
loss of function variant in PTPN22 that decreases the risk of
Crohn’s disease but increases the risk of rheumatoid arthri-
tis and type 1 diabetes [50]. Another interesting example
is the TNFRSF1A locus (electronic supplementary material,
table S1), where the same allele increases the risk of multiple
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Figure 3. Genes involved in pleiotropy. Barplot of the 40 genes in the NHGRI GWAS catalogue (www.genome.gov/gwastudies, accessed 23 October 2014) that have
the highest number of associations where they are listed as the reported gene. Genes in the MHC region have been excluded. Colours show the number of
associations that are attributed to each different category of study phenotypes.
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sclerosis but decreases the risk of ankylosing spondylitis (AS).
Intriguingly, this mimics the effect of response to anti-TNF
treatment which can reduce symptoms of AS, but increased
the relapse rate of multiple sclerosis in a clinical trial.
There are a number of associations shared between infec-
tious disease and non-infectious disease, highlighting the fact
that pleiotropy can potentially lead to conflicting evolution-
ary pressures. Specific examples include susceptibility loci
for inflammatory bowel disorder (IBD) and mycobacterial
infection, including at the gene NOD2, where a variant
upstream of NOD2 reduces risk of IBD but increases risk of
leprosy. The MHC region is a classic example where HLA
alleles are strongly linked to both autoimmune disease risk
and susceptibility to infectious diseases. Those confirmed
by GWAS include the alleles DRB1*15 (which protects from
visceral leishmaniasis [51] and leprosy [52], but increases
the risk of MS [17]) and HLA-B57 (which is associated with
slowed HIV progression [53] but increases AS risk [54]).
Beyond autoimmune disease, variants around the APOL1
locus (electronic supplementary material, table S1) that
reduce susceptibility to trypanosome infection increase the
risk of two specific types of kidney disease in individuals
with African ancestry [55].
One common approach to detecting pleiotropy is to com-
pare the lists of SNPs significantly associated with each
phenotype separately. This will typically underestimate the
extent of pleiotropy because SNPs with real effects may
happen not to reach significance for one or other phenotype
(depending on the sample size). Instead, it is more natural to
jointly model the effect of a SNP across different phenotypes.
These model comparison approaches are better powered to
detect pleiotropyandprovide a better assessment of the genetic
relationship between diseases [56]. They can even increase
power to detect association for individual phenotypes [57].
The genetic relationship between diseases can be
studied via polygenic effects as well as at individual loci.
For example, a recent study of five psychiatric diseases
reported significant genome-wide genetic correlations
among several pairs of traits, including a genetic correlation
of 0.68 for schizophrenia and bipolar disorder [58]. A more
recent study of 276 genetic correlations among 24 traits
with publicly available GWAS summary statistics reported
significant genome-wide genetic correlations for many
traits, including positive genetic correlations between schizo-
phrenia and anorexia nervosa, and between autism and
educational attainment [59].
6. Rare variant association studies
The genotyping arrays used in GWAS studies predominantly
typed common variants. As a consequence, these studies are
unable to systematically identify associations involving rare
variants (including rare copy number variants), which could
potentially contribute substantially to the genetic architecture
of commondisease [42]. A full appreciation of the genetic archi-
tecture of common disease requires direct assessment of the
role of rare variants. In addition knowledge of rare risk alleles
can point to potential novel therapeutic targets—even if they
explain little genetic variance. This has motivated rare variant
association studies, including exome sequencing and whole-
genome sequencing studies. Particular sets of rare variants
can also be assayed by genotyping technologies including the
so-called exome arrays or genome-wide arrays with millions
of markers.
The standard paradigm in rare variant association studies
is to aggregate rare variants in each gene and use genes as the
unit of association, via either a burden test that assumes uni-
form effects or an overdispersion test that allows for varying
effects [60]; other biological units of association (e.g. enhan-
cers) can also be used. Although exome and whole-genome
sequencing have been extremely effective in the context of
Mendelian disease, its results for common disease have
been mixed, with large investments in the past few years pro-
ducing a limited number of clear successes [61]. It had been
argued in advance of these studies that they would probably
detect rare variants of large or moderate effects on common
disease, but it is becoming clear that few such variants
exist with frequencies large enough for detection via this
approach. However, exome sequencing studies that do not
identify any individually significant genes can still be lever-
aged to detect and quantify polygenic signals [62], just as
in GWAS [41]. An interesting strategy in the Icelandic popu-
lation (for which GWAS array data are available for a
substantial fraction of the population) has been to use long-
range phasing of a target sample genotyped on GWAS
arrays to impute variants from a small subset of sequenced
individuals [63]. This approach has been particularly effective
(e.g. compared with 1000 Genomes imputation studies) in
identifying associations involving individual rare variants
as well as aggregate gene-level associations involving sets
of rare coding variants [64–66], highlighting the advantages
of a close match between the reference panel and the target
population when imputing rare variants.
7. Future directions
Over the past decade, the ability to assay genome-wide genetic
variation in large numbers of individuals has led to a trans-
formation in our knowledge of genetic variants associated
with common human diseases: there are now over 10 000
published associations between DNA sequence variants and
human diseases and traits. These findings have already deliv-
ered critical new insights intomany of the diseases studied. For
a typical disease, there will be a large number of common
variants (probably thousands), each of individually small
effect, that collectively explain a substantial portion of the gen-
etic component of the disease. As existing data resources are
leveraged using more sophisticated analytical approaches
(e.g. analyses across diseases) and integration of different
data types (e.g. functional annotation data), our understanding
will grow further. Although substantial resources have already
been spent on sequence-based studies of common diseases,
these have as yet delivered relatively modest additional find-
ings. As larger and better-powered sequencing studies are
undertaken, knowledge of disease-associated rare variants
should increase considerably. Sequencing studies are provid-
ing a more comprehensive catalogue of common and rare
variants in the genome, which is informative in a number of
contexts, including fine mapping.
While the pace of genetic discovery fuelled by GWAS
has been extraordinary and has already delivered many
important new insights into disease, systematic progress on
understanding the functional mechanism of individual
GWAS loci is lagging well behind their discovery. In large
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part, this reflects our relative lackof knowledge about and tools
for unravelling gene regulation, as well as the challenge of
identifying and studying the correct tissue, developmental
stage and potential external stimulus. Another factor has
been that groups responsible for genetic discovery are often
not best suited to undertake functional follow-up. However,
we are approaching a tipping point for understanding
and interpreting GWAS loci. The ENCODE and Roadmap
Epigenomics projects and other technological developments
have greatly expanded both our background knowledge of
gene regulation and the set of tools available for studying it.
Methods for assessing chromatin accessibility (e.g. DNase-
Seq, ATAC-seq), chromatin confirmation (e.g. 3C, 4C, 5C,
Hi-C, capture-C) and the epigenetic marks associated with
expression and repression of genes, together with new technol-
ogies such as the CRISPR-Cas9 genome editing system [67],
now complement established genetic approaches and poly-
genic analyses, and offer great promise for tackling the
biology underlying GWAS associations.
The next wave of genetic discovery in common diseases is
likely to be driven by the growth of large population biobanks
that combine genome-wide genetic information (currently geno-
typing arrays but in time sequence data) with extensive
phenotypic information and in some cases lifestyle, diet and
otherenvironmental exposures,allmeasuredonthesame individ-
uals (e.g. UKBiobank, a prospective studyof 500 000 individuals;
seeWeb resources). Large sample sizes are an obvious advantage
of these studies for genetic discovery (recall figure 2), but theywill
also substantially increase our understanding of gene–gene and
of gene–environment interactions. In addition, they facilitate
assessment of the consequences of particular genetic variants
on many phenotypes: the so-called PheWAS (phenome-wide
association studies). In turn, as noted above, this offers the poten-
tial to disentangle causal relationships from epidemiological
correlations using the so-called Mendelian randomization [46].
Genomics has the potential to make a significant impact
on drug development pipelines. These are facing major
challenges, with only a small proportion (less than 5%) of
potential drugs successful in reaching the market, and esti-
mated development costs per successful drug in the billions
of dollars [68]. It has been argued that most of this failure
is due to the inadequacies of preclinical models of disease,
and our lack of understanding of human biology [68]. Criti-
cally, human genetic approaches provide the opportunity to
learn about human biology in humans, rather than in
model systems. This applies to both target discovery and
target validation. First, genetic findings from both common
and rare diseases can point to novel drug targets (i.e. the
choice of a gene in which to intervene and the direction in
which to modulate it). Second, genetics can also be used in
target validation. A drug aims to intervene in human biology
by altering the activity of a specific gene in a particular way,
with the aim of improving a desired outcome. Genetics can
be helpful here through what has been called ‘Nature’s clini-
cal trial’. To assess the therapeutic hypothesis underpinning
the drug target, researchers can find individuals who, by
chance, carry genetic variants whose consequences are simi-
lar to those of the drug. For example, if the drug inhibits a
specific gene, one could study individuals with genetic
variants which result in downregulation of the gene, or var-
iants knocking out the function of one or both copies of the
gene. If the therapeutic hypothesis is valid, these naturally
occurring changes should also improve the desired outcome.
Recent empirical studies have shown that the existence of
supporting human genetic evidence substantially increases
the chances of success for a drug [69]. This experiment can
also be informative for assessing drug safety and possible
side effects: if individuals carrying genetic variants that
mimic the effect of the drug are at higher risk of another
disease or condition, then this could point to a safety risk for
the drug. Existing GWAS datasets and the growth of large
population biobanks offer unprecedented opportunities to rea-
lize some of the potential for genetics to impact on drug
development pipelines. As larger datasets are generated and
analysed, genetics is also likely to be helpful in stratifying
patient populations and moving from ‘one size fits all’ to
more personalized choices of treatments.
Looking forward, genetic information will come to be col-
lected more in clinical contexts than, as has happened to date,
in research studies. Rapid decreases in costs are bringing
genome sequencing closer to routine clinical care, with
countries and healthcare systems already embarking on pro-
jects to sequence large numbers of patients (e.g. Genomics
England and Geisinger whole exome and whole genome
sequencing; see Web resources). Genome sequencing will
yield clinical insights beyond what could be obtained from
genotyping arrays. Whole-genome and whole-exome sequen-
cing has had, and will continue to have, a major impact on
identifying the mutations causing rare genetic conditions.
As has always been the case in human genetics, these find-
ings point directly to gene function. The consequences for
common diseases of extensive sequencing will depend on
the contribution of rare variants to common disease [42].
Nonetheless, integration of complementary functional infor-
mation from both rare and from common diseases promises
to greatly increase our understanding of human biology.
We hypothesize that within 10–15 years, there will be
1 billion individuals sequenced globally, and in many cases
this information will be linked to their electronic medical
records. If the challenges of data accessibility and intero-
perability can be overcome (e.g. Global Alliance for Genomics
& Health; see Web resources), these resources will be trans-
formative. Genetics will become an empirical big-data science:
to understand the consequences of a particular mutation or
the likely outcomes of different treatment choices, or to assess
disease risk, sophisticated analytical tools will extrapolate
from the data of genetically similar individuals under similar
conditions. The progress of the past decade is often referred
to as the genetic revolution. The imminence of ubiquitous
genome sequencing means that a second genetic revolution is
now under way.
8. Web resources
NHGRI GWA Catalogue: http://www.genome.gov/GWA
Studies and http://www.ebi.ac.uk/fgpt/gwas/.
Haplotype Reference Consortium: http://www.haplo
type-reference-consortium.org/.
UK Biobank: http://www.ukbiobank.ac.uk/.
UK Biobank documentation for genotype imputation and
genetic association studies: http://biobank.ctsu.ox.ac.uk/
crystal/refer.cgi?id=157020.
Genomics England: http://www.genomicsengland.co.
uk/.
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Geisinger whole genome sequencing: http://www.
geisinger.org/for-researchers/initiatives-and-projects/pages/
whole-genome-sequencing.html.
Global Alliance for Genomics & Health: http://genomic
sandhealth.org/.
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